Volume 15, Issue 9 pp. 991-994

A novel presenilin 1 mutation (V261L) associated with presenile Alzheimer’s disease and spastic paraparesis

P. E. Jiménez Caballero

P. E. Jiménez Caballero

Alzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Virgen de la Salud, Toledo, Spain

Search for more papers by this author
C. De Diego Boguna

C. De Diego Boguna

Alzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Virgen de la Salud, Toledo, Spain

Search for more papers by this author
E. Martin Correa

E. Martin Correa

Alzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Virgen de la Salud, Toledo, Spain

Search for more papers by this author
M. Serviá Candela

M. Serviá Candela

Alzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Virgen de la Salud, Toledo, Spain

Search for more papers by this author
C. Marsal Alonso

C. Marsal Alonso

Alzheimer’s Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Virgen de la Salud, Toledo, Spain

Search for more papers by this author
First published: 11 August 2008
Citations: 10
Pedro Enrique Jiménez Caballero, Calle Murillo No 14, 45593 Bargas, Toledo, Spain (tel.: 0034925494121; fax: 0034925269258; e-mail: [email protected]).

Abstract

Background and purpose: We report a novel mutation in exon 8 of the presenilin 1 (PSEN1) gene (V261L) associated with early-onset autosomal dominant Alzheimer’s disease and spastic paraparesis.

Methods and results: The proband was a woman who developed insidious cognitive decline with predominant memory loss and gait disorder secondary to spasticity at the age of 40. Her brother and her mother had a similar disease in the fifth decade of life. The feature of amnestic presentation with spastic paraparesis is consistent with the majority of mutations in the exon 8 of the PSEN1 1 gene.

Conclusions: Screening for PSEN1 mutations is especially likely to be productive when directed toward persons with positive family history and with age at onset of under 60.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.